HK1250730A1 - 表皮生長因子受體變體iii-間皮素融合物及其使用方法 - Google Patents

表皮生長因子受體變體iii-間皮素融合物及其使用方法

Info

Publication number
HK1250730A1
HK1250730A1 HK18110071.1A HK18110071A HK1250730A1 HK 1250730 A1 HK1250730 A1 HK 1250730A1 HK 18110071 A HK18110071 A HK 18110071A HK 1250730 A1 HK1250730 A1 HK 1250730A1
Authority
HK
Hong Kong
Prior art keywords
mesothelin
fusions
methods
same
growth factor
Prior art date
Application number
HK18110071.1A
Other languages
English (en)
Inventor
P‧M‧勞爾
W‧G‧漢森
Original Assignee
艾杜羅生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾杜羅生物科技公司 filed Critical 艾杜羅生物科技公司
Publication of HK1250730A1 publication Critical patent/HK1250730A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18110071.1A 2015-04-13 2018-08-06 表皮生長因子受體變體iii-間皮素融合物及其使用方法 HK1250730A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562146559P 2015-04-13 2015-04-13
US201562243397P 2015-10-19 2015-10-19
PCT/US2016/027136 WO2016168198A1 (en) 2015-04-13 2016-04-12 Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same

Publications (1)

Publication Number Publication Date
HK1250730A1 true HK1250730A1 (zh) 2019-01-11

Family

ID=55809232

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18110071.1A HK1250730A1 (zh) 2015-04-13 2018-08-06 表皮生長因子受體變體iii-間皮素融合物及其使用方法
HK18110280.8A HK1250992A1 (zh) 2015-04-13 2018-08-10 表皮生長因子受體變體iii-間皮素融合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18110280.8A HK1250992A1 (zh) 2015-04-13 2018-08-10 表皮生長因子受體變體iii-間皮素融合物及其使用方法

Country Status (22)

Country Link
US (1) US10105427B2 (zh)
EP (1) EP3283509A1 (zh)
JP (1) JP6782253B2 (zh)
KR (1) KR20180002640A (zh)
CN (1) CN107750256A (zh)
AU (1) AU2016247887A1 (zh)
BR (1) BR112017022076A2 (zh)
CA (1) CA2982533A1 (zh)
CO (1) CO2017011431A2 (zh)
CR (1) CR20170507A (zh)
EA (1) EA201792274A1 (zh)
EC (1) ECSP17075380A (zh)
HK (2) HK1250730A1 (zh)
IL (1) IL254957A0 (zh)
MA (1) MA44379A (zh)
MX (1) MX2017013174A (zh)
PH (1) PH12017502080A1 (zh)
SG (1) SG11201708360TA (zh)
SV (1) SV2017005545A (zh)
TW (1) TW201710285A (zh)
UY (1) UY36616A (zh)
WO (1) WO2016168198A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017022076A2 (pt) 2015-04-13 2018-08-14 Aduro Biotech, Inc. fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
AU2016247894A1 (en) 2015-04-13 2017-10-26 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
AU2016369519B2 (en) 2015-12-16 2023-04-20 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
EP0796277B1 (en) 1994-11-28 2004-03-24 Thomas Jefferson University Fusion junction type iii mutant egf receptor peptide tumour vaccine
AU2001255196A1 (en) 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
JP2006514823A (ja) 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
AU2004224425B2 (en) 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4545151B2 (ja) 2003-02-06 2010-09-15 シーラス コーポレイション 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
ATE546153T1 (de) 2003-06-17 2012-03-15 Mannkind Corp Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
EP1991263B8 (en) * 2006-03-01 2015-02-25 Aduro Biotech Engineered listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
DK2640842T3 (en) * 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
MX2015008329A (es) * 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
CN104211814A (zh) * 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
AU2016247894A1 (en) 2015-04-13 2017-10-26 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
BR112017022076A2 (pt) 2015-04-13 2018-08-14 Aduro Biotech, Inc. fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas

Also Published As

Publication number Publication date
AU2016247887A1 (en) 2017-11-02
IL254957A0 (en) 2017-12-31
HK1250992A1 (zh) 2019-01-18
SV2017005545A (es) 2018-05-11
TW201710285A (zh) 2017-03-16
UY36616A (es) 2016-10-31
ECSP17075380A (es) 2018-02-28
EP3283509A1 (en) 2018-02-21
EA201792274A1 (ru) 2018-02-28
CR20170507A (es) 2018-02-13
JP2018512166A (ja) 2018-05-17
WO2016168198A1 (en) 2016-10-20
MX2017013174A (es) 2018-04-11
US10105427B2 (en) 2018-10-23
MA44379A (fr) 2019-01-23
PH12017502080A1 (en) 2018-05-07
KR20180002640A (ko) 2018-01-08
CA2982533A1 (en) 2016-10-20
JP6782253B2 (ja) 2020-11-11
CO2017011431A2 (es) 2018-01-16
BR112017022076A2 (pt) 2018-08-14
CN107750256A (zh) 2018-03-02
US20160346369A1 (en) 2016-12-01
SG11201708360TA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
HK1259019A1 (zh) 抗pd1抗體及使用方法
IL275944B (en) Fusion protein of interleukin-2 and receptor for interleukin-2 alpha and methods of use
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1247569A1 (zh) 抗pvrig抗體和使用方法
PL3368571T3 (pl) Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
IL259150B (en) Pyrimidine derivative and use thereof
HK1243444A1 (zh) 長效的ctp修飾的生長激素多肽的製備方法
IL246528B (en) Fusion protein inhibiting angiogenesis or growth and use thereof
LT3551209T (lt) Insulino-fc suliejimai ir panaudojimo būdai
HK1250992A1 (zh) 表皮生長因子受體變體iii-間皮素融合物及其使用方法
GB201519128D0 (en) Solid forms and methods of preparing the same
HK1248122A1 (zh) 抗met抗體及其使用方法
PL3110447T3 (pl) Przeciwciało anty-EGFR i jego zastosowania
HK1258850A1 (zh) 抗tpbg抗體及使用方法
ZA202002041B (en) Epidermal growth factor receptor inhibitors